Clinical Characteristics and Risk Factors for COVID-19-associated Candidemia

Omrani, Ali S; Koleri, Junais; Abid, Fatma Ben; Daghfel, Joanne; Odaippurath, Thasneem; Peediyakkal, Mohamed Zuhail; Baiou, Anas; Sarsak, Enas; Elayana, Mahmoud; Kaleeckal, Anvar; Almaslamani, Muna A

Patients with COVID-19-associated candidemia (CAC) in an intensive care unit (ICU) were matched 1:2 with those without candidemia, based on ICU admission date and length of stay in ICU being at least equal to that before candidemia in the corresponding case. The incidence rate of CAC was 2.34 per 1,000 ICU days. Eighty cases could be matched to appropriate controls. In the multivariate conditional logistic regression analysis, age (P 0.001), and sequential organ failure assessment score (P 0.046) were the only risk factors independently associated with CAC. Tocilizumab and corticosteroids therapy were not independently associated with candidemia. LAY SUMMARY: In COVID-19 patients who need medical care in an intensive care unit, the risk of developing bloodstream Candida infection is higher in older patients and in those who have a more severe critical illness. Treatment with steroids or tocilizumab does not seem to affect the risk of candida bloodstream infection in these patients.